

EudraCT number: 2008-007495-20

Sponsor Company: F. Hoffmann-La Roche Ltd

Study Title: A single arm, open-label, multicentre, phase II study to evaluate the efficacy and safety of bevacizumab and trastuzumab combination and sequential capecitabine in patients with HER2-positive locally recurrent or metastatic breast cancer after early relapse to adjuvant trastuzumab-containing therapy

The study ML22056 was planned to be conducted in Austria. However, no subjects were enrolled, and the study ended prematurely. Consequently, study results will not be submitted.